Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.36 |
| ▸ | VCP | P55072 | 3/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751685 | 1.00 | CYP11B1 (0.38) | CYP11B1KDM1ACYP11B2VCPCYP19A1 | |
| SCHEMBL3751690 | 1.00 | CYP11B1 (0.38) | CYP11B1KDM1ACYP11B2VCPCYP19A1 | |
| SCHEMBL3749376 | 0.90 | DPP4 (0.39) | VCPDPP4GRM5INPPL1LMNA | |
| SCHEMBL3749384 | 0.90 | DPP4 (0.39) | VCPDPP4GRM5INPPL1LMNA | |
| SCHEMBL3749382 | 0.90 | DPP4 (0.39) | VCPDPP4GRM5INPPL1LMNA | |
| SCHEMBL3747806 | 0.89 | DPP4 (0.39) | CYP19A1DPP4ALDH1A1 | |
| SCHEMBL3747802 | 0.89 | DPP4 (0.39) | CYP19A1DPP4ALDH1A1 | |
| SCHEMBL3747798 | 0.89 | DPP4 (0.39) | CYP19A1DPP4ALDH1A1 | |
| SCHEMBL3752840 | 0.86 | CYP11B1 (0.39) | CYP11B1KDM1ACYP11B2VCPCYP19A1 | |
| SCHEMBL3752846 | 0.86 | CYP11B1 (0.39) | CYP11B1KDM1ACYP11B2VCPCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2007-03-01 | — | — | US | claimed |
| EP-1919854-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7834012-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | CYP11B1 2314/4885KDM1A 2597/4885CYP11B2 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.